Israel · Delayed Price · Currency is ILS · Price in ILA Bio-View Statistics
Total Valuation
Bio-View has a market cap or net worth of ILS 21.58 million. The enterprise value is 17.15 million.
| Market Cap | 21.58M |
| Enterprise Value | 17.15M |
Important Dates
The last earnings date was Friday, April 10, 2026.
| Earnings Date | Apr 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bio-View has 134.01 million shares outstanding. The number of shares has increased by 2.13% in one year.
| Current Share Class | 134.01M |
| Shares Outstanding | 134.01M |
| Shares Change (YoY) | +2.13% |
| Shares Change (QoQ) | +4.97% |
| Owned by Insiders (%) | 50.18% |
| Owned by Institutions (%) | 16.96% |
| Float | 66.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.08 |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.12 |
| EV / Sales | 0.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.51 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.88 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.90 |
| Interest Coverage | -65.13 |
Financial Efficiency
Return on equity (ROE) is -94.76% and return on invested capital (ROIC) is -155.36%.
| Return on Equity (ROE) | -94.76% |
| Return on Assets (ROA) | -18.11% |
| Return on Invested Capital (ROIC) | -155.36% |
| Return on Capital Employed (ROCE) | -68.68% |
| Weighted Average Cost of Capital (WACC) | 3.62% |
| Revenue Per Employee | 664,333 |
| Profits Per Employee | -511,067 |
| Employee Count | 31 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.44 |
Taxes
In the past 12 months, Bio-View has paid 6.19 million in taxes.
| Income Tax | 6.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.90% in the last 52 weeks. The beta is -0.11, so Bio-View's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | -47.90% |
| 50-Day Moving Average | 16.33 |
| 200-Day Moving Average | 18.36 |
| Relative Strength Index (RSI) | 51.41 |
| Average Volume (20 Days) | 213,210 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio-View had revenue of ILS 19.93 million and -15.33 million in losses. Loss per share was -0.11.
| Revenue | 19.93M |
| Gross Profit | 9.52M |
| Operating Income | -7.75M |
| Pretax Income | -9.15M |
| Net Income | -15.33M |
| EBITDA | -7.35M |
| EBIT | -7.75M |
| Loss Per Share | -0.11 |
Balance Sheet
The company has 7.22 million in cash and 2.79 million in debt, with a net cash position of 4.43 million or 0.03 per share.
| Cash & Cash Equivalents | 7.22M |
| Total Debt | 2.79M |
| Net Cash | 4.43M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 9.42M |
| Book Value Per Share | 0.07 |
| Working Capital | 7.55M |
Cash Flow
In the last 12 months, operating cash flow was -3.06 million and capital expenditures -53,000, giving a free cash flow of -3.11 million.
| Operating Cash Flow | -3.06M |
| Capital Expenditures | -53,000 |
| Depreciation & Amortization | 405,000 |
| Net Borrowing | -1.70M |
| Free Cash Flow | -3.11M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 47.76%, with operating and profit margins of -38.89% and -76.93%.
| Gross Margin | 47.76% |
| Operating Margin | -38.89% |
| Pretax Margin | -45.90% |
| Profit Margin | -76.93% |
| EBITDA Margin | -36.86% |
| EBIT Margin | -38.89% |
| FCF Margin | n/a |
Dividends & Yields
Bio-View does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.13% |
| Shareholder Yield | -2.13% |
| Earnings Yield | -71.06% |
| FCF Yield | -14.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 24, 2023. It was a forward split with a ratio of 10.
| Last Split Date | Dec 24, 2023 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
Bio-View has an Altman Z-Score of -1.05 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.05 |
| Piotroski F-Score | 3 |